The association between raised plasma cholesterol and cardiovascular risk is well established, with consistent evidence associating LDL-cholesterol reduction with a reduction in primary and secondary cardiovascular events. It is believed that intensive lipid lowering may improve clinical outcomes further by acting to stabilise plaque and preventing plaque progression, ultimately reducing plaque vulnerability. However, it remains uncertain whether a continued clinical benefit occurs with intensive lipid lowering or if there is a threshold level below which no further benefit occurs.
- CRP, C-reactive protein
- HMG-CoA, 3-hydroxy-3-methylglutaryl coenzyme A
- IL-6, interleukin-6
- M-CSF, macrophage-colony stimulating factor
- MI, myocardial infarction
- PPAR, peroxisome proliferator-activated receptor
- hydroxymethylglutaryl-CoA reductase inhibitors
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.